Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations

Zwitter, Matjaž; Rajer, Mirjana; Stanič, Karmen; Vrankar, Martina; Doma, Andrej; Cuderman, Anka; Grmek, Marko; Kern, Izidor; Kovac,

doi:10.1080/15384047.2016.1195049

Cited by 22 publications

(25 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So far, however, there only relatively few and mostly small studies comparing RECIST and PERCIST (References: [17] [42] [43] [44] [45] [46] [47] [48] [20] [49] [50] [51] [21] [52] [53] [24] [23] [25] [54] [26] [55] [56]). A meta-analysis published in 2016 identified 6 studies including 268 patients [57].…”

Section: Limitations Of Recist and Opportunities For Fdg Pet Based Rementioning

confidence: 99%

Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments

Pinker

Riedl

Weber

2017

Eur J Nucl Med Mol Imaging

126

View full text Add to dashboard Cite

Eighteen years ago, the EORTC PET criteria standardized for the first-time response assessment by FDG PET. Response assessment by FDG PET has been further developed and refined by PERCIST (PET response criteria in solid tumors). This review describes the data underlying these two systems for assessing tumor response on FDG PET/CT. It also summarizes recent clinical studies that have compared EORTC criteria and PERCIST with each other as well as with the anatomically based “response criteria in solid tumors” (RECIST). These studies have shown that response assessment by EORTC criteria and PERCIST leads to very similar response classifications. In contrast, there are significant differences between response assessment by PERCIST and RECIST. Preliminary data also suggest that response assessment by PERCIST is better correlated with patient outcome and may be a better predictor for the effectiveness of new anti-cancer therapies than RECIST. If correct, this could have a significant impact on oncologic drug development. However, confirmation of the better predictive value of response assessment by PERCIST by data from randomized trials is still lacking.

show abstract

Section: Limitations Of Recist and Opportunities For Fdg Pet Based Rementioning

confidence: 99%

Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments

Pinker

Riedl

Weber

2017

Eur J Nucl Med Mol Imaging

126

View full text Add to dashboard Cite

show abstract

“…At present, the EGFR- tyrosine kinase inhibitor (TKI) treatment is a standard and first line therapy for NSCLC patients having EGFR-activating mutations[4]. However, acquired resistance often occurs after EGFR- tyrosine kinase inhibitor (TKI) therapy[5,6]. The occurrence of T790M in exon 20 of the EGFR gene is the most common resistance mechanism in NSCLC patients with EGFR-TKI therapy[7,8].…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs

Zhang

Wei

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

ObjectiveEpidermal growth factor receptor (EGFR) specific mutations have been known to improve survival of patients with non-small-cell lung carcinoma (NSCLC). However, whether there are any changes of EGFR mutations after targeted therapy and its clinical significance is unclear. This study was to identify the status of EGFR mutations after targeted therapy and predict the prognostic significance for NSCLC patients.MethodsA total of forty-five (45) NSCLC patients who received EGFR-TKI therapy were enrolled. We identified the changes of EGFR mutations in plasma ctDNA by Amplification Refractory Mutation System (ARMS) PCR technology.ResultsIn the 45 cases of NSCLC with EGFR mutations, the EGFR mutation status changed in 26 cases, in which, 12 cases (26.7%) from positive to negative, and 14 cases (31.1%) from T790M mutation negative to positive after TKI targeted therapy. The T790M occurance group had a shorter Progression -Free-Survival (PFS) than the groups of EGFR mutation undetected and EGFR mutation turned out to have no change after EGFR-TKI therapy (p < 0.05).ConclusionsAccording to this study, it’s necessary to closely monitor EGFR mutations during follow-up to predict the prognosis of NSCLC patients who are to receive the TKI targeted therapy.

show abstract

“…[20][21][22][23][24][25][26] Urothelial cancer is the most agressive disease and have a low response rate especially after the firstline therapy in its advanced stage. The treatment break for patients who responded to first-line therapy is generally shortterm for about 2 to 3 months and it leads to rapid clinical progression and deterioration.…”

Section: Discussionmentioning

confidence: 99%

Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival

Kuş

Aktaş

2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: To investigate the effects of gemcitabine maintenance treatment on survival in patients with metastatic bladder cancer. Material and methods:Gemcitabine maintenance monotherapy was administered following the standard platinum-gemcitabine therapy in patients with metastatic bladder cancer. Patients who had responded to standard treatment received maintenance gemcitabine therapy as 1000 mg/m 2 on days 1 and 8 every three weeks until progression or development of unacceptable toxicity. The following clinical factors were noted: performance status, age, sex, stage, site of metastasis, choice of cisplatin-gemcitabine or carboplatin-gemcitabine, response rates to the initial chemotherapy. Progression-free survival (PFS) and overall survival (OS) for standard treatment, and following gemcitabine monotreatment and for maintenance gemcitabine therapy were calculated using Kaplan-Meier method.Results: A total of 88 patients with metastatic bladder cancer treated between February 2009 to October 2015 were evaluated retrospectively and 23 patients (26.1%) who had responded to six cycles of platinumgemcitabine treatment were included in this study. Maintenance gamcitabine was administered for a median of 7 times (range 3-14 times). Grade 3 hematotoxicity according to the criteria of the Common Terminology Criteria of Adverse Events was observed in 7 (30.4%) patients. Median PFS of patients was 46 (range: 30-82) weeks for platinum-based treatment plus maintenance gemcitabine therapy. A higher median PFS was obtained in patients who were <65 year-olds, without organ metastasis with objective response rate, however, it was statistically insignificant. Conclusion:Gemcitabine maintenance therapy in metastatic bladder cancer patients who did not shown progression after the standard platinum-gemcitabine treatment contributes to survival and presents low toxicity profile, when compared to historical controls.

show abstract

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations

Cited by 22 publications

References 41 publications

Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments

Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs

Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival

Contact Info

Product

Resources

About